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Mantle cell lymphoma patients have variable clinical courses,ranging from indolent cases that do not require immediate treat-ment to aggressive, rapidly progressing diseases. Thus, diagnos-
tic tools capable of stratifying patients according to their risk of relapse
and death are needed. This study included 83 samples from the
Fondazione Italiana Linfomi MCL-0208 clinical trial. Through gene
expression profiling and quantitative real-time PCR we analyzed 46
peripheral blood and 43 formalin-fixed paraffin-embedded lymph node
samples. A prediction model to classify patients was developed. By ana-
lyzing the transcriptome of 27 peripheral blood samples, two subgroups
characterized by a differential expression of genes from the B-cell recep-
tor pathway (B-cell receptorlow and B-cell receptorhigh) were identified.
The prediction model based on the quantitative real-time PCR values of
six representative genes (AKT3, BCL2, BTK, CD79B, PIK3CD, and SYK),
was used to classify the 83 cases (43 B-cell receptorlow and 40 B-cell
receptorhigh). The B-cell receptorhigh signature associated with shorter pro-
gression-free survival (P=0.0074), selected the mantle cell lymphoma
subgroup with the shortest progression-free survival and overall survival
(P=0.0014 and P=0.029, respectively) in combination with high (>30%)
Ki-67 staining, and was an independent predictor of short progression-
free survival along with the Mantle Cell Lymphoma International
Prognostic Index-combined score. Moreover, the clinical impact of the 6-
gene signature related to the B-cell receptor pathway identified a mantle
cell lymphoma subset with shorter progression-free survival intervals
also in an external independent mantle cell lymphoma cohort homoge-
nously treated with different schedules. In conclusion, this 6-gene signa-
ture associates with a poor clinical response in the context of the MCL-
0208 clinical trial. (clinicaltrials.gov identifier: 02354313).
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ABSTRACT
Introduction
Mantle cell lymphoma (MCL) is a distinctive B-cell
malignancy accounting for 5-10% of all lymphomas,1-3
whose molecular hallmark and initiating oncogenic event,
the t(11;14)(q13;q32) translocation, leads to constitutive
overexpression of the proto-oncogene cyclin D1
(CCND1).2,4
Once considered as uniformly characterized by a poor
prognosis, MCL has been demonstrated to have unexpect-
edly variable clinical courses, ranging from indolent cases
that do not require immediate treatment to aggressive,
rapidly progressing disease.2,5-10 Even among patients
requiring treatment, prognosis is highly heterogeneous,
with patients experiencing prolonged remissions and oth-
ers rapidly relapsing even after cytarabine-containing
induction regimens followed by autologous transplanta-
tion. Thus, diagnostic tools capable of stratifying MCL
patients in different risk classes are warranted in order to
direct treatment strategies.11 For this reason, many
attempts have been made to identify clinical, histological,
and molecular markers that can stratify patients according
to their risk of relapse and death.12-25
In addition to the clinical MCL prognostic score (MCL-
International Prognostic Index, MIPI)12,14 capable  of strati-
fying patients into risk groups with different overall sur-
vival (OS),14 the Ki-67 proliferation index has been pro-
posed as one of the most powerful and independent pre-
dictors of survival in MCL even in the context of prospec-
tive trials and modern therapies,5,13,26 and for these reasons
has been integrated into the so-called MIPI-combined
(MIPI-c) score.13,26 Moreover, effective prognostic discrimi-
nation is achieved by post-treatment response monitoring
by positron emission tomography (PET)-scan and minimal
residual disease (MRD). Furthermore, a seminal study
identified a specific signature associated with proliferation
as the strongest predictor of OS in a large MCL series.20 In
this context, a cohort of 20 proliferation-associated genes
constructed on the basis of gene expression analysis was
demonstrated to be superior to other molecular markers.20
Since approaches based on microarray technology have
not yet been incorporated into routine clinical practice, a
PCR-based surrogate method investigating expression of
five genes has been proposed and applied to paraffin-
embedded tissues.18
Recent evidence suggests that the B-cell receptor (BCR)
pathway may contribute to the pathogenesis of several
histological types of B-cell non-Hodgkin lymphomas,
including MCL.27-30 The importance of BCR signaling path-
way in B-cell malignancy pathogenesis has driven interest
in the use of small-molecule inhibitors of BCR-associated
kinases, potentially preventing the activation of one or
more of the distal BCR signaling pathway proteins.28,31
In the present study, we developed a survival predictive
model for younger patients with advanced MCL treated in
the context of the Fondazione Italiana Linfomi (FIL) MCL-
0208 Phase III randomized clinical trial. This model is
based upon the quantitative evaluation of six genes, most-
ly from the BCR pathway, selected from a gene expression
profile (GEP) of peripheral blood (PB) MCL cells  and was
applied  to formalin-fixed paraffin-embedded (FFPE) tissue
specimens. Notably, the model predicts poor response in
the context of the FIL-MCL-0208 trial. 
Methods
Primary MCL cases
The study included 83 out of 300 samples of adult patients
under 66 years of age with advanced stage MCL, enrolled in the
FIL-MCL-0208 prospective, multicenter, Phase III randomized
clinical trial (clinicaltrials.gov identifier: 02354313),32 divided as fol-
lows: i) a panel of 27 PB samples utilized for GEP upon positive
sorting of the clonal CD5+/CD19+ MCL cells; ii) an additional
panel of 19 PB samples utilized for quantitative real-time PCR
(qRT-PCR) of the identified gene signature in the purified MCL
cell component; iii) a panel of 43 lymph node (LN) samples uti-
lized for qRT-PCR of the identified gene signature (in this LN
panel 6 samples had a matched PB sample). The clinical and histo-
pathological details of the 83 MCL cases used in this study are
reported in Table 1. No significant differences were found
between the 83 cases entering the study versus the 217 remaining
cases enrolled in the clinical trial in terms of median age, MIPI
score, Ki-67 index and PFS intervals (Online Supplementary Table S1
and Online Supplementary Figure S1). No differences in clinical and
biological parameters were observed between PB and LN MCL
samples  (data not shown). All patients were treated according to the
FIL-MCL-0208 clinical trial, as reported in Online Supplementary
Figure S2. 
Mantle cell lymphoma diagnosis was prospectively confirmed
by centralized histological review according to the  World Health
Organization (WHO) 2008  criteria.3,33 All patients provided
informed consent in accordance with Institutional Review Board
requirements (0016331-BZ 09/02/2010) and the Declaration of
Helsinki, and protocol consent included use of MRD sample left-
overs for the study.
All the procedures employed for RNA extraction, GEP and
downstream analyses, qRT-PCR, analyses and qRT-PCR valida-
tions were carried out  according to standard protocols, as report-
ed previously.34-37 (See the Online Supplementary Appendix for
details). Microarray data are available in Gene Expression
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Table 1. Characteristics of 83 mantle cell lymphoma cases entering
the study.
Samples
Number of cases 83
Median age,  years (range) 56 (28-65)
Ratio male/female (%) 57/26 (68)
Abnormal LDH (%) 45/29 (39)
Median WBC (x109/L) 13.7
Typical morphology 74
Blastoid morphology 5
Median Proliferation Index (Ki-67 staining), % 20.0 (0-99)
MIPI-c class
Low 38 (46%)
Low/intermediate 23 (28%)
High/intermediate 11 (13%)
High 6 (7%)
na 5 (6%)
Median survival, months (range) 34.7 (1.4-73.4)
Median progression-free survival, months (range) 31.3 (1.4-73.4)
LDH: lactate dehydrogenase; WBC: white blood count; MIPI-c: MCL:-International
Prognostic Index-combined; na: not available.
Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession num-
ber GSE89447. Cases used for these procedures are reported in
Online Supplementary Table S2.
Validation procedures
The 6-gene signature was tested in the MCL cohort described
by Saba et al.,30 enrolled in another clinical trial (clinicaltrials.gov
identifier: 00114738), by using the sum of the array gene expression
values, as reported.30 Gene signatures related to MCL outcome
were retrieved from previous papers,30,38 and imported in the
GeneSpring GX and tested in the present cohort with GEP data
available.
Statistical analysis
Overall survival was computed from trial registration to death
as a result of any cause, censored at the latest follow up in patients
who were still alive. Progression-free survival (PFS) was computed
from trial registration to progression or death as a result of any
cause, censored at the latest tumor assessment if no progression
was observed. Clinical correlations, performed with the MedCalc
v.9.5 software, were made using Kaplan-Meier plots and log-rank
test. The Cox proportional model was chosen for multivariable
analysis. Clinical outcome results were up-dated as of January
2017.32 Investigators are still blinded to the investigation arm as
the  primary study end point has still not been met. 
Results
GEP identifies MCL patients with distinct expression of
genes belonging to the BCR pathway
Global GEP was performed in purified MCL cells from
27 PB samples. An unsupervised analysis performed by
principal component analysis (PCA) divided the cohort
into two groups of 14 cases and 13 cases, respectively
(Figure 1A). Consistently, a hierarchical clustering, which
was run with all the GEP features, split MCL cases into
two major groups perfectly resembling the PCA groups
(Figure 1B).
Supervised analysis according to the PCA classification
defined a gene expression signature composed of  922
probes, 713 up-regulated and 209 down-regulated in
group-2 versus group-1 samples (Figure 1C and Online
Supplementary Table S3).
Pathway analysis revealed that “Antigen processing and
presentation” and “B-cell receptor signaling pathway”
were among the top ranked pathways enriched in the
B-cell receptor signature in mantle cell lymphoma
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Figure 1. Gene Expression Profile (GEP) analysis of 27 mantle cell lym-
phoma samples. (A) Principal Component Analysis (PCA) scores represent-
ed in a 3D scatter plot. One point per array/sample is shown. Black line indi-
cates separation between PCA classes. (B) Hierarchical clustering of 14
group-1 cases and 13 group-2 cases, using 50,739 probes. (C) Hierarchical
clustering of 14 group1 cases and 13 group2 cases, using the 922 differ-
entially expressed probes. Color codes for gene expression values refer to
mean centered log-ratio values.
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group-2 category (Online Supplementary Table S4). Similar
results were obtained by GSEA which highlighted a con-
stitutive overexpression of genes related to the BCR sig-
naling pathways in the context of group-2 patients (Figure
2A and Online Supplementary Table S5). Therefore, here-
after the two PCA groups were identified as BCRlow
(group-1) and BCRhigh (group-2).
A 6-gene signature identifies BCRlow and BCRhigh MCL
samples
Having identified two different groups of MCL patients
at diagnosis with a different expression of genes related
to the BCR pathway, we overlapped the genes included in
the gene sets related to the BCR pathway (115 probes)
and the differentially expressed genes (922 probes) to cre-
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Figure 2. 6-gene signature and Decision Tree (DT) prediction model. (A) Gene Expression Profile data of BCRlow and BCRhigh MCL samples were tested using Gene set
enrichment analysis (GSEA). Reported are the significant gene sets differentially expressed and related to the B-Cell Receptor (BCR) pathway. (B) Venn diagram
derived by merging the differentially expressed probes and the genes belonging to the BCR related gene sets. In bold genes selected as the 6-gene signature. (C)
Hierarchical clustering of 14 BCRlow cases and 13 BCRhigh cases, using the six gene values. Color codes for gene expression values refer to mean centered log-ratio
values. (D) Hierarchical clustering of 8 BCRlow cases and 9 BCRhigh cases belonging to the training set of DT prediction model, using the six gene qRT-PCR values. (E)
Hierarchical clustering of 6 BCRlow cases and 4 BCRhigh cases belonging to the validation set of DT prediction model, using the six gene qRT-PCR values. Bar under the
heat-map refers to prediction generated by the DT prediction model. Color codes for gene expression values refer to mean centered log-ratio values.
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ate a reduced signature (Figure 2B). In this way, 18 probes
corresponding to 15 genes, all over-expressed in BCRhigh
cases were identified (Figure 2B). Among these genes, a
subgroup of six genes (AKT3, BCL2, BTK, CD79B,
PIK3CD, and SYK) was selected for further validations
due to their direct involvement in the BCR pathway
and/or the existence of drugs targeting the related pro-
teins. A hierarchical cluster using only these six genes was
able to discriminate patients belonging to the BCRlow or
BCRhigh groups (Figure 2C).
Development of a qRT-PCR-based predictor for BCRlow
and BCRhigh in MCL samples
By analyzing the expression levels of the selected six
genes in the same 27 MCL PB samples by qRT-PCR
approach, a strict correlation with GEP data was found
(Online Supplementary Figure S3B). Moreover, the 27 MCL
cases were randomly divided into a training set (17 cases;
8 BCRlow and 9 BCRhigh samples) and a validation set (10
cases; 6 BCRlow and 4 BCRhigh samples) to develop and test
a decision tree (DT) model based on qRT-PCR data capa-
ble of categorizing patients into one of the two categories.
The DT model based on qRT-PCR data correctly classified
16 of 17 cases belonging to the training set and 10 of 10
cases of the validation cohort, and allowed the classifica-
tion of 19 additional PB samples screened with qRT-PCR
(9 BCRlow and 10 BCRhigh (Figure 2D and E and Online
Supplementary Table S2).
Association between BCR categories and biological
and clinical parameters
Collectively, the 6-gene signature was re-evaluated by
setting up a validated qRT-PCR approach (see Online
Supplementary Appendix and Online Supplementary Table S6)
in PB samples from 46 MCL cases, 23 were identified as
BCRlow and 23 as BCRhigh. By correlating the BCR groups
with the available biological parameters, no association
was found between the 6-gene signature and IGHV gene
status (P=0.93) (Online Supplementary Table S2 and Online
Supplementary Figure S4A), Ki-67 expression, white blood
cells, hemoglobin, lymphocytes, platelets, and neutrophil
count (data not shown). The only significant difference was
between the BCR classification and lactate dehydrogenase
(LDH)  levels;  BCRhigh cases showed a higher level of LDH
with respect to BCRlow MCL (416.6±191.6 vs. 292.2±127.4;
P=0.023) (Online Supplementary Figure S4B).
Clinically, MCL patients classified as BCRhigh experi-
enced shorter PFS with respect to BCRlow MCL cases
(median PFS: 21.6 months vs. not reached; P=0.0375)
(Figure 3). 
Application of the 6-gene signature to LN samples
from MCL patients
To evaluate the capability of the 6-gene signature to
identify different subgroups also in the context of MCL
LN cases, we tested our qRT-PCR approach in a series of
43 LN samples preserved as FFPE LN specimens. Thirty-
five (81%) out of 43 samples were amplifiable for all six
genes, and  using a DT model based on qRT-PCR values
from FFPE, 23 cases were classified as BCRlow and 20 clas-
sified as BCRhigh (Online Supplementary Table S2). Notably,
for 6 out of 43 LN samples, a PB matched sample was
available, and by comparing qRT-PCR results performed
on PB samples and LN FFPE samples from these cases, a
good concordance was overall observed, although FFPE
samples generally amplified at higher Ct values (Online
Supplementary Figure S5). Of note, 5 out of 6 these MCL
cases were consistently classified. The misclassified case
B-cell receptor signature in mantle cell lymphoma
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Table 2. Cox regression analysis on mantle cell lymphoma cases.
Univariable Multivariable
Variable HR (95%CI) P HR (95%CI) P
BCR signature
BCR high 2.81 (1.28-6.19) 0.01 3.48 (1.47-8.25) 0.005
MIPI-c
Low/intermediate 1.5 (0.6-3.73) 0.384
High/intermediate 1.41 (0.45-4.43) 0.557
High 3.46 (1.1-10.91) 0.034 4.17 (1.3-13.34) 0.016
Multivariable Cox regression analysis of progression-free survival was performed by including the 6-gene BCR categorization and the mantle cell lymphoma International
Prognostic Index-combined (MIPI-c) score as defined by Hoster et al.13 HR: Hazard Ratio; CI: Confidence Interval; BCR: B-cell receptor. 
Figure 3. BCRhigh mantle cell lymphoma (MCL) group is associated with a worse
clinical outcome. Kaplan-Meier curves obtained by comparing progression-free
survival intervals of 23 BCRlow MCL cases with 23 BCRhigh MCL cases. The number
of patients in each group is reported under relative categories; P refers to log-
rank test.
was considered as BCRlow according to GEP data. Also in
the context of LN samples, no correlation was found
between the different biological parameters and BCR
groups (data not shown). 
By merging the MCL cases analyzed either in PB or in
LN, a total of 83 cases were collected, 43 BCRlow and 40
BCRhigh. BCRhigh patients had a shorter PFS with respect to
BCRlow patients (median PFS: 42.1 months vs. not reached;
P=0.0074) (Figure 4A). Since Ki-67 is a well-known prog-
nosticator in MCL,26 we combined the BCR groups with
the prognostic groups defined by Ki-67 score. Cases with
high Ki-67 (≥30% of Ki-67 expressing cells) and classified
in the BCRhigh group experienced the shortest PFS, while
cases classified as BCRlow had similar longer PFS intervals
irrespective of the high or low Ki-67 score (median PFS:
20.5 months vs. not reached for all the other combinations;
P=0.0014) (Figure 4B). Consistently, multivariable analysis
carried out by including the BCR signature and the MIPI-c
categories selected the BCRhigh and the high risk MIPI-c cat-
egory as independent predictors of PFS (Table 2). Regarding
OS, while the BCR readout failed to identify groups with
different OS intervals, possibly due to the low rate of
events and short follow up (Figure 4C), the combination of
high Ki-67 score and a BCRhigh 6-gene signature was able
again to select the MCL subgroup with the shortest OS
(46.7 vs. not reached; P=0.029) (Figure 4D).
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Figure 4. BCRhigh mantle cell
lymphoma (MCL) group is
associated with a worse clini-
cal outcome (overall series).
(A) Kaplan-Meier curves
obtained by comparing pro-
gression-free survival (PFS)
intervals of 43 BCRlow MCL
cases with 40 BCRhigh MCL
cases. (B) Kaplan-Meier
curves obtained by compar-
ing PFS intervals of 19 BCRlow
and low Ki-67 MCL cases,
with 20 BCRlow and high Ki-67
MCL cases, with 21 BCRhigh
and Ki-67 low MCL cases,
with 10 BCRhigh and Ki-67 high
MCL cases. (C) Kaplan-Meier
curves obtained by compar-
ing overall survival (OS) inter-
vals of 43 BCRlow MCL cases
with 40 BCRhigh MCL cases.
(D) Kaplan-Meier curves
obtained by comparing OS
intervals of 19 BCRlow and low
Ki-67 MCL cases, with 20
BCRlow and high Ki-67 MCL
cases, with 21 BCRhigh and Ki-
67 low MCL cases, with 10
BCRhigh and Ki-67 high MCL
cases. The number of
patients in each group is
reported under relative cate-
gories; P refers to log-rank
test.
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Validations of BCR signature
To verify whether the BCR signature maintained its
prognostic impact in an independent set of patients, we
used the gene expression data of MCL LN biopsies report-
ed by Saba et al.30 Also in this different setting, a high
expression of the 6-gene signature, as in the context of
BCRhigh cases, identified an MCL patient subset with infe-
rior PFS (P=0.049) (Online Supplementary Figure S6).
In another set of analyses, by taking advantage of our 27
MCL cases with GEP data available, we correlated our
BCR signature with other MCL signatures with proven
clinical impact.30,38 As reported in Online Supplementary
Figure S7A, the BCR signature reported in Saba et al.30
divided MCL cases in two groups that corresponded
exactly  to our BCR definition (Online Supplementary Figure
S7B).30 Similarly, the 17 genes of the proliferation signa-
ture reported by Scott et al.38 split our MCL cases in 3 dif-
ferent groups resembling the 3 different groups originally
defined (Online Supplementary Figure S8A). In this context,
the shortest PFS and OS intervals were observed in the
third group characterized by a higher expression of genes
related to proliferation and a BCRhigh phenotype in keeping
with our findings (Online Supplementary Figure S8A-C).
Discussion
In this study, we demonstrated that a BCR-derived sig-
nature based on the differential expression of six genes
correlated with shorter PFS intervals in the context of a
Phase III prospective clinical trial (FIL-MCL-0208) for
younger MCL patients receiving R-CHOP induction, fol-
lowed by high-dose cytarabine and autologous stem cell
transplantation (clinicaltrials.gov identifier: 023541313).32
Notably, the BCR-related 6-gene signature reported here
was able to identify an MCL subset with shorter PFS inter-
vals also in the context of an external independent MCL
cohort homogenously treated with different schedules.30
On the other hand, when the signature described by Saba
et al.30 and Scott et al.38 was applied to our MCL cases, the
patient subsets with the worse prognosis turned out to be
particularly enriched in BCRhigh cases, even though these
signatures did not include any gene from our signature.
Therefore, although composed of genes located upstream
of the BCR machinery, our signature was able to identify
cases with an active BCR pathway as defined by other sig-
natures.30 In this regard, however, experiments with pri-
mary MCL cases and/or MCL cell lines combining BCR
stimulation with the use of specific BCR inhibitors should
be performed to investigate the contribution of the 6-gene
signatures described here to the actual activation of the
BCR pathway.
Again in agreement with this line of reasoning, BCRhigh
samples presented a significant upregulation of PAX5 (see
GEP data in Online Supplementary Table S3), a gene whose
product is known to prevent plasma cell differentiation
thus preserving the capacity to respond to antigen-
induced activation and proliferation.39 Taken together
these data corroborate recent findings of ongoing active
BCR signaling in MCL cell in vivo,29,30 and further underline
the role of antigen stimulation in the ontogeny of MCL, as
suggested by the skewed IGVH gene repertoire found in
MCL cells.40
In order to discriminate between BCRlow and BCRhigh
MCL samples, we developed a DT model based on the
expression of the selected six genes.28 This DT model was
applied in an independent cohort of PB samples and then
to a further series of FFPE LN samples, thus demonstrating
that two MCL subsets with different expression levels of
BCR-related genes could  also be  recognized  in the LN
compartment, mirroring PB. Taken together, by combin-
ing data from the PB and LN compartments, MCL cases
classified as BCRhigh showed higher LDH levels and shorter
PFS with respect to BCRlow patients, suggesting that activa-
tion of BCR signaling drives tumor proliferation and deter-
mines clinical outcome of MCL patients, which is in keep-
ing with recent findings.30
By combining the predictive capacity of the 6-gene BCR
signature with the Ki-67 index, we identified a particularly
unfavorable category (BCRhigh and high Ki-67) with a sub-
stantially shorter PFS and OS than the other groups.
Consistently, the BCRhigh signature turned out to be an
independent prognosticator along with the high-risk
MIPI-c category for short PFS by multivariate analysis.
There is no indication that the validity of the model may
be affected by the different recruitment site (PB vs. LN), or
by different sample storage (frozen vs.  FFPE) because the
main clinical parameters were equally distributed
between the different series (PB/frozen vs. LN/FFPE) (R
Bomben et al., 2018, unpublished observation). In this regard,
an important feature of this model/assay is its applicabili-
ty to both PB and LN FFPE samples, having, therefore, the
chance to combine results of qRT-PCR with Ki-67 staining
in all the cases.
Our data underscore the increasing importance of BCR-
related genes in the pathogenesis and development of
MCL, further underlined by the clinical significance of
drugs specifically targeting genes belonging to this path-
way. In particular, therapeutic targeting of BTK41 can be
rationally exploited in lymphoid malignancies that have
been proved to be dependent on  an antigen-dependent
BCR-mediated active signaling. However, despite the rel-
atively high response rate to single agent ibrutinib in
relapsed/refractory MCL, it remained unclear as to why
some patients showed clear responses, while others
received little therapeutic benefit.31,42 The BCR-related sig-
nature described here may provide insights into molecular
factors that explain the divergent responses of MCL
patients to ibrutinib, although other causes of primary
resistance might be related to gene mutations in the other
pathways, e.g. NF-κB pathway and epigenetic modifiers,
as recently reported.43,44
In conclusion, in the present study we developed a sur-
vival model for patients with MCL composed of six genes
(AKT3, BTK, CD79B, PIK3CD, SYK, BCL2) whose expres-
sion can easily be investigated by qRT-PCR and also in
FFPE specimens. The signature was associated with a poor
clinical response in the context of a high-dose chemo-
immunotherapy regimen, and might,  therefore, be con-
sidered for validation and application in future clinical tri-
als.
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